Bitter melon peptide fermentation particle structure

Abstract

A bitter melon peptide fermentation particle structure comprising: a particle body having the shape of a round sphere, containing a natto bacterial ferment and a bitter melon extract, and formed by co-fermenting the natto bacterial ferment and the bitter melon extract in a ratio of 1:1 to 1:4.

Description

Technical area

[0001] The present utility model relates to a particulate structure, in particular a bitter melon peptide fermentation particle structure, which is particularly suitable for health products for diabetes and related metabolic diseases. Technology in the background

[0002] Diabetes mellitus is a chronic metabolic disease primarily caused by a lack of insulin or a weakened tissue response to insulin, which leads to impaired glucose metabolism and ultimately triggers the phenomenon of hyperglycemia. When the glucose concentration in the blood is too high and exceeds the absorption limit of the kidneys, the glucose is excreted in the urine, resulting in glycosuria. Depending on the cause of the disease, diabetes mellitus can be divided into type 1 diabetes and type 2 diabetes. Type 1 diabetes is insulin-dependent because the pancreas cannot secrete insulin, while type 2 diabetes is non-insulin-dependent because it results from insulin tolerance or insufficient insulin secretion.Both type 1 and type 2 diabetics experience symptoms of high blood sugar levels, and studies have shown that about 80% of type 2 diabetics also suffer from obesity.

[0003] The key to improving type 2 diabetes is maintaining stable blood sugar levels and losing weight. Patients should avoid sweets, sugary drinks, alcohol, and high-sugar fruits and combine these with regular exercise. They may also consider taking supplements that help lower blood sugar levels.

[0004] Research has shown that bitter melon extract has multiple effects, such as antioxidant, antihypertensive, anti-lipid, anti-hyperglycemic, and anti-metabolic, with its anti-hyperglycemic effect being particularly important. Therefore, further discovery of compounds with significant therapeutic effects on diabetes would be highly desirable and would contribute to effectively improving people's health problems. Content of the utility model

[0005] The creator of this utility model has studied the above-mentioned problems in detail and finally introduced this utility model after a series of trials and improvements.

[0006] The utility model is a bitter melon peptide fermentation particle structure comprising: a particle body, the particle body is round and spherical, contains natto bacterial ferment and bitter melon extract, and the natto bacterial ferment and the bitter melon extract are co-fermented in a ratio of 1:1~1:4.

[0007] In one of the embodiments of the utility model, the bitter melon peptide fermentation particle structure also includes a protective layer wrapped around the outside of the particle body to prevent external environmental factors from affecting the activity of the particle body, thereby improving the storage stability and the absorption rate of the particle body by the human body.

[0008] The main purpose of this bitter melon peptide fermentation particle structure is that the particle body is round and spherical, achieving better biocompatibility. It can reduce irritation to the human body and promote uniform release of the health-promoting effects, thereby improving efficacy and reducing side effects, improving drug solubility and promoting absorption, and helping diabetics and people at risk of hyperglycemia achieve health management by improving blood sugar control and promoting metabolism. Description of the attached drawings Fig. 1 is a three-dimensional sectional view of the utility model. Fig. 2 is a plan view of the utility model. Fig. 3 is a schematic representation of the utility model filled into the capsule. Fig. Figure 4 is a diagram showing the expression of genes related to glucose uptake under different conditions. Fig. Figure 5 is a diagram showing the expression of insulin-associated genes under different conditions.

[0009] Symbol description: 10 particle body; 11 natto bacterial ferment; 12 bitter melon extract; 20 protective layer; 30 capsule Detailed description

[0010] The following figures of better embodiments of the utility model are described in more detail below to enable persons familiar with the relevant technology of the utility model to implement it in accordance with the description of the present specification.

[0011] First, referring to the first figure and the second figure, this utility model has a bitter melon peptide fermentation particle structure comprising: a particle body 10 and a protective layer 20.

[0012] The particle body 10 is round and spherical and contains natto bacterial ferment 11 and bitter melon extract 12. The natto bacterial ferment 11 and bitter melon extract 12 are co-fermented in a ratio of 1:1~1:4, and the particle body 10 is in a homogeneous state to ensure the efficacy and stability of the product. The particle structure 10 not only preserves the nutritional components of bitter melon but also enhances its biological activity through the nattokinase fermentation process, thereby improving its effect on blood sugar control. The above ratio of 1:1~1:4 refers to the ratio of the mass of natto bacterial ferment 11 to the mass of bitter melon extract 12. Through the scientific fermentation process, these components work together to regulate blood sugar levels and improve insulin sensitivity.

[0013] The protective layer 20 is wrapped around the outer surface of the particle body 10 to prevent external environmental influences from affecting the activity of the particle body 10, thereby improving the storage stability and human absorption rate of the particle body 10. The protective layer 20 ensures that the active ingredients of the particle body 10 are not lost during storage and use. The design of the protective layer 20 takes into account the release characteristics of the particle body 10 to ensure that the active ingredient can be gradually released in the body to improve its bioavailability, allowing the nutritional components of the particle body 10 to be better absorbed in the digestive tract, thereby improving its effect on blood sugar control.

[0014] When the bitter melon peptide fermentation particles are consumed, in addition to direct oral intake, a predetermined amount of the bitter melon peptide fermentation particles may be filled into the capsule 30 as shown in the third figure, and the capsule 30 may be used for swallowing.

[0015] With the development of science and technology, the application of bitter melon peptide fermented particles is promising. It is predicted that the product is not only suitable for daily health care for diabetics, but can also be marketed as a health food to meet consumer demand for natural and effective health care products. Furthermore, by combining modern nutritional science and food science, more complex health products based on bitter melon peptide fermented particles can be developed in the future.

[0016] To verify the effectiveness of the present utility model, an experiment was conducted on the performance of genes associated with glucose uptake, see Fig. 4, which represents the expression of genes related to glucose uptake under different conditions, where the vertical axis represents the ratio of gene expression relative to gene performance / GAPDH and the horizontal axis represents different experimental groups;

[0017] Normal: This group represents the normal or untreated state.

[0018] Bitter gourd: This group represents the condition treated with bitter gourd.

[0019] Bitter Melon Natto: This group represents the condition treated with the utility model Bitter Melon Peptide Fermentation Particles.

[0020] The legend illustrates the genes represented by the different colored bars: : SLC2A2 (glucose transporter protein 2, GLUT2), : SLC2A4 (glucose transporter protein 4, GLUT4), : SLC2A9 (glucose transporter protein 9, GLUT9). : SLC2A10 (glucose transporter protein 10, GLUT10), : SLC5A3 (sodium / glucose cotransporter protein 3, SGLT3).

[0021] Out of Fig. Figure 5 shows that the present invention, bitter melon peptide fermentation particles, positively regulates the expression of various glucose transport protein genes, particularly SLC2A2, SLC2A10, and SLC5A3. These glucose transporter proteins perform important glucose transport functions in various tissues and cells of the body. These results indicate that the novel bitter melon peptide fermentation particle structure has some effect on glucose metabolism.

[0022] In addition to conducting experiments on insulin-induced gene expression, Fig. 5, which shows the expression of insulin-associated genes under different conditions, where the vertical axis represents the ratio of gene expression to gene expression / GAPDH and the horizontal axis represents the different experimental groups: NC (Negative Control): This group represents the basal or untreated state. Bitter gourd: This group represents the condition after treatment with bitter gourd. Bitter Melon Natto: This group represents the condition treated with the bitter melon peptide fermentation particle utility model.

[0023] The legend illustrates the genes represented by the different colored bars: : INSR (insulin receptor), : IRS1 (insulin receptor substrate 1), : IDE (insulin-degrading enzyme), INSIG2 (insulin-inducible gene 2), : IGFIR (insulin-like growth factor 1 receptor). : IGF2 (insulin-like growth factor 2), : IGFBP1 (insulin-like growth factor binding protein 1), : IGFBP4 (insulin-like growth factor binding protein 4).

[0024] Out of Fig. Figure 5 shows that the present invention, bitter melon peptide fermentation particles, can significantly increase the expression of the INSIG2 gene when used. For other insulin-related genes studied, treatment with the invention, bitter melon peptide fermentation particles, had a relatively small effect on their expression.

[0025] From the structure of the above specific embodiment, the following advantages can be obtained: The bitter melon peptide fermentation particle structure of the utility model, with its rounded sphere-shaped particulate body 10, achieves better biocompatibility, can reduce stimulation of the human body, and makes its distribution more uniform, thereby promoting the release of health benefits, improving therapeutic efficacy, and reducing side effects. Fermentation and micronization can significantly improve its water solubility, thereby promoting intestinal absorption. This helps diabetics and people at risk of high blood sugar achieve health management by improving blood sugar control and promoting metabolism, which has broad application potential in the health field.

Claims

[1] A bitter melon peptide fermentation particle structure comprising: a particle body having the shape of a round sphere, containing a natto bacterial ferment and a bitter melon extract, and formed by co-fermenting the natto bacterial ferment and the bitter melon extract in a ratio of 1:1 to 1:

4. [2] A bitter melon peptide fermentation particle structure according to claim 1, further comprising a protective layer wrapped around the outer side of the particle body to prevent external environmental factors from affecting the activity of the particle body, so as to improve the storage stability and the absorption rate of the particle body by the human body [3] A bitter melon peptide fermentation particle structure according to claim 1, wherein the particle body is in a homogeneous state.

Images